RNA结合蛋白QKI-5、Ezrin在浆液性卵巢癌中的研究
|
摘要
目的检测RNA结合蛋白QKI-5、Ezrin在浆液性卵巢癌中的表达,探讨其在浆液性卵巢癌发生发展中的作用。方法选取2012年至2017年在浙江大学舟山医院就诊且诊断为浆液性卵巢癌的患者40例及正常女性20例为研究对象,采用免疫组化的方法对卵巢组织标本中的RNA结合蛋白QKI-5、Ezrin的表达进行检测,对结果进行分析,并比较两者之间的相关性。结果与对照组相比,QKI-5mRNA、Ezrin在浆液性卵巢癌患者卵巢组织中的表达均显著的下调,差异均具有统计学的意义(t值分别为2.71、3.72,均P<0.05)。浆液性卵巢癌组织样品中Ezrin阳性率为97.50%,对照组卵巢上皮组织细胞中Ezrin阳性率为100.00%,两组之间比较无显著性差异(χ~2=0.51,P=0.48)。结论 RNA结合蛋白QKI-5、Ezrin的表达下调与浆液性卵巢癌患者肿瘤的发生发展等临床病理过程相关,这两个指标有望成为卵巢癌的早期诊断指标,并可能为卵巢癌患者临床治疗提供新思路。
Objective To detect the expressions of RNA-binding proteins QKI-5 and Ezrin in serous ovarian carcinoma and to explore their correlation with the occurrence and development of serous ovarian carcinoma.Methods Forty patients with serous ovarian carcinoma diagnosed in Zhoushan Hospital of Zhejiang University from 2012 to 2017 and 20 normal women were enrolled in this study.Expressions of RNA-binding proteins QKI-5 and Ezrin in ovarian tissue samples were detected by immunohistochemistry,results were analyzed,and correlation between them was explored.Results Expressions of QKI-5 mRNA and Ezrin in ovarian tissue in serous ovarian carcinoma patients were significantly down-regulated when compared with those in normal controls,and differences were statistically significant(t value was 2.71 and 3.72,respectively,both P <0.05).Ezrin positive rate in serous ovarian carcinoma patients was 97.50%,while positive rate of Ezrin in ovarian epithelial cells in normal controls was 100.00%.There was no significant difference between two groups(χ~2=0.51,P=0.48).Conclusion Down-regulation of expressions of RNA binding-proteins QKI-5 and Ezrin is closely related to pathological process such as tumor occurrence and development in serous ovarian cancer patients,so these two indicators are expected to be early diagnostic indexes for ovarian cancer,and they provide new ideas for clinical treatment of ovarian cancer patients.
Objective To detect the expressions of RNA-binding proteins QKI-5 and Ezrin in serous ovarian carcinoma and to explore their correlation with the occurrence and development of serous ovarian carcinoma.Methods Forty patients with serous ovarian carcinoma diagnosed in Zhoushan Hospital of Zhejiang University from 2012 to 2017 and 20 normal women were enrolled in this study.Expressions of RNA-binding proteins QKI-5 and Ezrin in ovarian tissue samples were detected by immunohistochemistry,results were analyzed,and correlation between them was explored.Results Expressions of QKI-5 mRNA and Ezrin in ovarian tissue in serous ovarian carcinoma patients were significantly down-regulated when compared with those in normal controls,and differences were statistically significant(t value was 2.71 and 3.72,respectively,both P <0.05).Ezrin positive rate in serous ovarian carcinoma patients was 97.50%,while positive rate of Ezrin in ovarian epithelial cells in normal controls was 100.00%.There was no significant difference between two groups(χ~2=0.51,P=0.48).Conclusion Down-regulation of expressions of RNA binding-proteins QKI-5 and Ezrin is closely related to pathological process such as tumor occurrence and development in serous ovarian cancer patients,so these two indicators are expected to be early diagnostic indexes for ovarian cancer,and they provide new ideas for clinical treatment of ovarian cancer patients.
引文
[1]薛艳,曾宪玲,岳婷,等.卵巢囊肿蒂扭转在绝经后与育龄期患者中的临床特征比较[J].中国妇幼健康研究,2016,27(11):1399-1401.
[2]Ledermann J,Harter P,Gourley C,et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer:a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial[J].Lancet Oncol,2014,15(8):852-861.
[3]Dong L,Qin S,Li Y,et al.High expression of astrocyte elevated gene-1 is associated with clinical staging,metastasis,and unfavorable prognosis in gastric carcinoma[J].Tumour Biol,2015,36(3):2169-2178.
[4]郑智国,夏婷,牟瀚舟,等.血清多肽谱对高级别浆液性卵巢癌诊断价值分析[J].中华肿瘤防治杂志,2014,21(20):1633-1636.
[5]Demacopulo B,Lema B E,Cabrini R L,et al.Similar expression pattern of NHERF1 and EZRIN in papillary but not in solid areas of human serous ovarian carcinomas[J].Acta Histochem,2016,118(8):797-805.
[6]Perets R,Wyant G A,Muto K W,et al.Transformation of the fallopian tube secretory epithelium leads to highgrade serous ovarian cancer in Brca;Tp53;Pten models[J].Cancer Cell,2013,24(6):751-765.
[7]Li J,Li L,Li Z,et al.The role of miR-205 in the VEGFmediated promotion of human ovarian cancer cell invasion[J].Gynecol Oncol,2015,137(1):125-133.
[8]刘菲,姚丽,张佳瑞,等.miR-129-1-3p在浆液性卵巢癌中的表达及临床意义[J].现代肿瘤医学,2014,22(8):1921-1924.
[9]Ghaffari A,Hoskin V,Mullins G,et al.Real-time imaging of lymph node metastasis in response to systemic ezrin inhibitor treatment in breast cancer[J].Cancer Res,2016,76(4 Suppl):Abstract nr P5-01-01.
[10]文峰,陈兰,程建国,等.Ezrin和CD_(44)在胃癌组织中的表达及临床意义[J].实用临床医药杂志,2014,18(3):19-22.
[11]Lu W,Feng F,Xu J,et al.QKI impairs self-renewal and tumorigenicity of oral cancer cells via repression of SOX2[J].Cancer Biol Ther,2014,15(9):1174-1184.
[12]Zhang R L,Yang J P,Peng L X,et al.RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA[J].Cell Cycle,2016,15(22):3094-3104.
[13]Zhao Y,Zhang G,Wei M,et al.The tumor suppressing effects of QKI-5 in prostate cancer:a novel diagnostic and prognostic protein[J].Cancer Biol Ther,2014,15(1):108-118.
[14]Li F,Yi P,Pi J,et al.QKI5-mediated alternative splicing of the histone variant macroH2A1 regulates gastric carcinogenesis[J].Oncotarget,2016,7(22):32821-32834.
[15]王玉娣,章建国,刘益飞.shSASH1基因对卵巢癌细胞SKOV3生物学功能的影响[J].中国妇幼健康研究,2016,27(12):1475-1478.
[16]Matsuura K,Huang N J,Cocce K,et al.Downregulation of the proapoptotic protein MOAP-1 by the UBR5ubiquitin ligase and its role in ovarian cancer resistance to cisplatin[J].Oncogene,2017,36(12):1698-1706.
[17]Wang J,Wu Q,Zhang L H,et al.The role of RhoA in vulvar squamous cell carcinoma:a carcinogenesis,progression,and target therapy marker[J].Tumor Biol,2016,37(3):2879-2890.
[18]杨洪颖,张文军,左燕红.胃癌组织中Ezrin表达与Bcl-2/Bax关系及其预后[J].解放军医药杂志,2015,27(1):78-81.
[19]Gadducci A,Guerrieri M E.PARP inhibitors in epithelial ovarian cancer:state of art and perspectives of clinical research[J].Anticancer Res,2016,36(5):2055-2064.
[20]Yan H,Qiu L,Xie X,et al.ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells[J].Oncol Rep,2017,37(3):1412-1418.
[2]Ledermann J,Harter P,Gourley C,et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer:a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial[J].Lancet Oncol,2014,15(8):852-861.
[3]Dong L,Qin S,Li Y,et al.High expression of astrocyte elevated gene-1 is associated with clinical staging,metastasis,and unfavorable prognosis in gastric carcinoma[J].Tumour Biol,2015,36(3):2169-2178.
[4]郑智国,夏婷,牟瀚舟,等.血清多肽谱对高级别浆液性卵巢癌诊断价值分析[J].中华肿瘤防治杂志,2014,21(20):1633-1636.
[5]Demacopulo B,Lema B E,Cabrini R L,et al.Similar expression pattern of NHERF1 and EZRIN in papillary but not in solid areas of human serous ovarian carcinomas[J].Acta Histochem,2016,118(8):797-805.
[6]Perets R,Wyant G A,Muto K W,et al.Transformation of the fallopian tube secretory epithelium leads to highgrade serous ovarian cancer in Brca;Tp53;Pten models[J].Cancer Cell,2013,24(6):751-765.
[7]Li J,Li L,Li Z,et al.The role of miR-205 in the VEGFmediated promotion of human ovarian cancer cell invasion[J].Gynecol Oncol,2015,137(1):125-133.
[8]刘菲,姚丽,张佳瑞,等.miR-129-1-3p在浆液性卵巢癌中的表达及临床意义[J].现代肿瘤医学,2014,22(8):1921-1924.
[9]Ghaffari A,Hoskin V,Mullins G,et al.Real-time imaging of lymph node metastasis in response to systemic ezrin inhibitor treatment in breast cancer[J].Cancer Res,2016,76(4 Suppl):Abstract nr P5-01-01.
[10]文峰,陈兰,程建国,等.Ezrin和CD_(44)在胃癌组织中的表达及临床意义[J].实用临床医药杂志,2014,18(3):19-22.
[11]Lu W,Feng F,Xu J,et al.QKI impairs self-renewal and tumorigenicity of oral cancer cells via repression of SOX2[J].Cancer Biol Ther,2014,15(9):1174-1184.
[12]Zhang R L,Yang J P,Peng L X,et al.RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA[J].Cell Cycle,2016,15(22):3094-3104.
[13]Zhao Y,Zhang G,Wei M,et al.The tumor suppressing effects of QKI-5 in prostate cancer:a novel diagnostic and prognostic protein[J].Cancer Biol Ther,2014,15(1):108-118.
[14]Li F,Yi P,Pi J,et al.QKI5-mediated alternative splicing of the histone variant macroH2A1 regulates gastric carcinogenesis[J].Oncotarget,2016,7(22):32821-32834.
[15]王玉娣,章建国,刘益飞.shSASH1基因对卵巢癌细胞SKOV3生物学功能的影响[J].中国妇幼健康研究,2016,27(12):1475-1478.
[16]Matsuura K,Huang N J,Cocce K,et al.Downregulation of the proapoptotic protein MOAP-1 by the UBR5ubiquitin ligase and its role in ovarian cancer resistance to cisplatin[J].Oncogene,2017,36(12):1698-1706.
[17]Wang J,Wu Q,Zhang L H,et al.The role of RhoA in vulvar squamous cell carcinoma:a carcinogenesis,progression,and target therapy marker[J].Tumor Biol,2016,37(3):2879-2890.
[18]杨洪颖,张文军,左燕红.胃癌组织中Ezrin表达与Bcl-2/Bax关系及其预后[J].解放军医药杂志,2015,27(1):78-81.
[19]Gadducci A,Guerrieri M E.PARP inhibitors in epithelial ovarian cancer:state of art and perspectives of clinical research[J].Anticancer Res,2016,36(5):2055-2064.
[20]Yan H,Qiu L,Xie X,et al.ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells[J].Oncol Rep,2017,37(3):1412-1418.